SADI Operations: Efficacy and Complications
Single-Anastomosis Duodeno-Ileal bypass with sleeve gastrectomy (SADI-S) is a safe and highly effective bariatric procedure that achieves sustained weight loss of approximately 33-34% total weight loss at 5 years, with diabetes remission rates of 63-78%, though it carries a 2-3% leak rate and requires vigilant long-term nutritional monitoring for protein malnutrition and micronutrient deficiencies.
Current Guideline Status
SADI-S (also termed OADS, SIPS) remains under review by the American Society for Metabolic and Bariatric Surgery (ASMBS) and has not been endorsed as a primary procedure due to lack of robust longer-term follow-up 1. However, the 2019 AACE/TOS/ASMBS guidelines acknowledge that these procedures have been shown to be safe and as effective as Roux-en-Y duodenal switch with a trend toward fewer nutritional deficiencies at mid-term (3-5 years) follow-up 1.
The procedure involves creating a sleeve gastrectomy (larger volume than primary sleeve) with duodenal transection and a loop duodenoileostomy, with the efferent alimentary limb varying from 150-300 cm 1.
Weight Loss Efficacy
Primary SADI-S Outcomes
The most recent systematic review of 5-year outcomes (2025) demonstrates robust efficacy 2:
- Mean preoperative BMI: 49.66 kg/m²
- 5-year total weight loss (TWL): 33.67%
- 5-year excess weight loss (EWL): 72.88%
- Final BMI at 5 years: 31.7 kg/m²
Revisional SADI-S After Failed Procedures
When used as a revisional procedure after failed adjustable gastric banding or sleeve gastrectomy 3, 4, 5:
- 12-month TWL: 23.78% (BMI change: 11.01 kg/m²)
- 24-month TWL: 27% (maximum)
- 36-month TWL: 21.03% (BMI change: 9.57 kg/m²)
- 60-month TWL: 22.11% (BMI change: 11.04 kg/m²)
Important caveat: Weight stabilization or slight regain occurs after 24 months in revisional cases, with TWL decreasing from 27% at 24 months to 24% at 60 months 5.
Metabolic Disease Resolution
SADI-S demonstrates superior metabolic outcomes compared to purely restrictive procedures:
Primary SADI-S
- Type 2 diabetes remission: 78.5% 6
- Hypertension resolution: 48-69% 3, 4
- Dyslipidemia resolution: 47-55% 3, 4
- Obstructive sleep apnea resolution: 69% 3
Revisional SADI-S (27-month average follow-up)
The higher preoperative diabetes severity in some cohorts makes these remission rates particularly impressive 6.
Complications Profile
Early Complications (≤30 days)
Short-term morbidity rate: 5.4-11.6% 2
Specific early complications include:
- Anastomotic leak/fistula: 2-5% 3, 2, 4, 5
- Reoperation rate: 5% 5
- Hemorrhage: Variable (included in overall morbidity)
- Mean operative time: 125.98 minutes 4
Mortality rate: 0.2-2% (consistently low across studies) 2, 5
Long-Term Complications (>30 days)
Long-term complication rate: 8.7-17.9% 2
Specific complications:
- Steatorrhea: 11.2% 3
- Diarrhea: 2-8.7% 3, 4
- Anemia: 5.7% 3
- GERD: 5.1% 3
- Nutritional deficiency: 4.2% 3
- Protein malnutrition: Critical concern, particularly with 200 cm common channel 2
Critical Nutritional Considerations
Malnutrition-related reoperations are specifically associated with a common channel length of 200 cm 2. This represents a modifiable surgical parameter that directly impacts long-term safety.
Required lifelong supplementation includes 7, 8:
- Thiamin
- Vitamin B12
- Folate
- Iron
- Vitamin D and calcium
- Vitamin A, E, K
- Zinc and copper
Structured postoperative monitoring is mandatory to prevent protein malnutrition, which represents the most serious long-term nutritional risk 2.
Comparative Effectiveness
In subgroup analyses comparing revisional procedures 3:
SADI-S vs. RYGB vs. OAGB:
- Weight loss: Comparable across all three procedures
- Comorbidity resolution: Comparable
- Stenosis/obstruction: Higher in RYGB
- Bile reflux: Higher in OAGB
- Overall safety profile: SADI-S comparable or favorable
When compared to LAGB and RYGB in patients ≥70 years, single-anastomosis duodenal switch was most effective for weight loss 1.
Clinical Decision Algorithm
Indications for SADI-S
Primary procedure consideration:
Revisional procedure indications:
- Failed sleeve gastrectomy (inadequate weight loss or weight regain)
- Failed adjustable gastric banding
- Suboptimal metabolic outcomes after primary restrictive procedure
Contraindications
- Severe GERD or hiatal hernia (relative contraindication, though some data suggest SADI-S can treat GERD with appropriate technique) 1
- Inability to comply with lifelong nutritional monitoring
- Severe protein malnutrition at baseline
Technical Considerations
- Common channel length: Use >200 cm to minimize malnutrition risk 2
- Alimentary limb length: 150-300 cm (surgeon preference and patient factors)
- Sleeve volume: Larger than primary sleeve gastrectomy 1
Follow-Up Requirements
Mandatory lifelong follow-up schedule:
- Every 4-6 weeks initially 11
- Regular nutritional monitoring with laboratory assessment
- Micronutrient supplementation adjustment based on levels
- Protein intake monitoring (critical)
- Weight and metabolic parameter tracking
Common pitfall: Inadequate long-term nutritional follow-up leads to preventable malnutrition complications. The 4.2% nutritional deficiency rate reflects cases where monitoring failed 3.
Evidence Quality Assessment
The evidence base for SADI-S consists primarily of observational studies and systematic reviews of case series. No large randomized controlled trials exist comparing SADI-S to established procedures 1. The 2019 AACE/ASMBS guidelines appropriately classify the evidence strength as requiring further validation before full endorsement 1.
The most robust data comes from the 2025 systematic review of 5-year outcomes 2 and the 2026 meta-analysis of revisional procedures 3, representing the highest quality evidence currently available for this procedure.